SECTION\ue000 1.\ue000 Registrant's\ue000 Business\ue000 and\ue000 Operations
None.
SECTION\ue000 2.\ue000 \ue000 Financial\ue000 Information
None.
SECTION\ue000 3.\ue000 \ue000 Securities\ue000 and\ue000 Trading\ue000 Markets
None.
SECTION\ue000 4.\ue000 \ue000 Matters\ue000 Related\ue000 to\ue000 Accountants\ue000 and\ue000 Financial\ue000 Statements
None.
SECTION\ue000 5.\ue000 \ue000 Corporate\ue000 Governance\ue000 and\ue000 Management
Item\ue000 5.02\ue000 Departure\ue000 of\ue000 Directors\ue000 or\ue000 Principal\ue000 Officers;\ue000 Election\ue000 of\ue000 Directors;\ue000 Appointment\ue000 of\ue000 Principal\ue000 Officers.
Effective\ue000 February\ue000 18th\ue000 2009,\ue000 the\ue000 Board\ue000 of\ue000 Directors\ue000 appointed\ue000 Ms.\ue000 Donna\ue000 A.\ue000 Lopolito\ue000 to\ue000 serve\ue000 as\ue000 Chief
Financial\ue000 Officer\ue000 of\ue000 the\ue000 Company.
Ms.\ue000 Lopolito,\ue000 a\ue000 Certified\ue000 Public\ue000 Accountant,\ue000 earned\ue000 a\ue000 Bachelor\ue000 of\ue000 Arts\ue000 degree\ue000 in\ue000 Accountancy\ue000 from\ue000 Bentley
College.\ue000 She\ue000 serves\ue000 both\ue000 private\ue000 and\ue000 public\ue000 companies,\ue000 with\ue000 experience\ue000 in\ue000 venture\ue000 capital\ue000 and\ue000 other\ue000 private
financings,\ue000 initial\ue000 public\ue000 offerings,\ue000 SEC\ue000 compliance,\ue000 and\ue000 public/investor\ue000 relations.
Ms.\ue000 Lopolito\ue000 was\ue000 a\ue000 Partner\ue000 with\ue000 PricewaterhouseCoopers,\ue000 and\ue000 has\ue000 served\ue000 a\ue000 Chief\ue000 Financial\ue000 Officer\ue000 for
thirteen\ue000 years,\ue000 primarily\ue000 in\ue000 the\ue000 life\ue000 sciences\ue000 arena.\ue000 Certain\ue000 companies\ue000 where\ue000 she\ue000 has\ue000 served\ue000 as\ue000 full-time\ue000 or\ue000 interim\ue000 CFO
include\ue000 Afferent,\ue000 AMAG,\ue000 Au\ue000 Bon\ue000 Pain,\ue000 Biolink,\ue000 Cambria,\ue000 Codon\ue000 Devices,\ue000 Genocea,\ue000 Gloucester\ue000 Pharmaceuticals,
Idera,\ue000 InfraReDx,\ue000 Interleukin\ue000 Genetics,\ue000 Modular\ue000 Genetics,\ue000 myvu,\ue000 Organogenesis,\ue000 Phylogix,\ue000 Spherics,\ue000 Xanthus,\ue000 and
ZoomInfo.
Ms.\ue000 Lopolito\ue000 is\ue000 an\ue000 active\ue000 member\ue000 and\ue000 former\ue000 President\ue000 of\ue000 the\ue000 Massachusetts\ue000 Society\ue000 of\ue000 Certified\ue000 Public
Accountants,\ue000 an\ue000 active\ue000 member\ue000 and\ue000 former\ue000 Council\ue000 Member\ue000 of\ue000 the\ue000 American\ue000 Institute\ue000 of\ue000 CPAs,\ue000 and\ue000 Chairman\ue000 of\ue000 the
Finance\ue000 Committee\ue000 for\ue000 the\ue000 Town\ue000 of\ue000 Easton.\ue000 Additionally,\ue000 she\ue000 is\ue000 also\ue000 a\ue000 member\ue000 of\ue000 the\ue000 Board\ue000 of\ue000 Directors\ue000 and\ue000 Audit
Committee\ue000 for\ue000 Independent\ue000 Bank\ue000 Corp\ue000 (Rockland\ue000 Trust).
Ms.\ue000 Lopolito\ue000 is\ue000 and\ue000 will\ue000 continue\ue000 to\ue000 be\ue000 an\ue000 employee\ue000 of\ue000 AccountAbility\ue000 Outsourcing\ue000 Inc.
SECTION\ue000 6.\ue000 [Reserved]
N/A.
SECTION\ue000 7.\ue000 \ue000 Regulation\ue000 FD
Item\ue000 7.01\ue000 Regulation\ue000 FD\ue000 Disclosure
Except\ue000 for\ue000 the\ue000 historical\ue000 information\ue000 presented\ue000 in\ue000 this\ue000 document,\ue000 the\ue000 matters\ue000 discussed\ue000 in\ue000 this\ue000 Form\ue000 8-K,\ue000 or\ue000 otherwise
incorporated\ue000 by\ue000 reference\ue000 into\ue000 this\ue000 document,\ue000 contain\ue000 "forward-looking\ue000 statements"\ue000 (as\ue000 such\ue000 term\ue000 is\ue000 defined\ue000 in\ue000 the
Private\ue000 Securities\ue000 Litigation\ue000 Reform\ue000 Act\ue000 of\ue000 1995).\ue000 These\ue000 statements\ue000 are\ue000 identified\ue000 by\ue000 the\ue000 use\ue000 of\ue000 forward-looking
terminology\ue000 such\ue000 as\ue000 "believes",\ue000 "plans",\ue000 "intend",\ue000 "scheduled",\ue000 "potential",\ue000 "continue",\ue000 "estimates",\ue000 "hopes",
"goal",\ue000 "objective",\ue000 expects",\ue000 "may",\ue000 "will",\ue000 "should"\ue000 or\ue000 "anticipates"\ue000 or\ue000 the\ue000 negative\ue000 thereof\ue000 or\ue000 other\ue000 variations
thereon\ue000 or\ue000 comparable\ue000 terminology,\ue000 or\ue000 by\ue000 discussions\ue000 of\ue000 strategy\ue000 that\ue000 involve\ue000 risks\ue000 and\ue000 uncertainties.\ue000 The\ue000 safe
harbor\ue000 provisions\ue000 of\ue000 Section\ue000 21E\ue000 of\ue000 the\ue000 Securities\ue000 Exchange\ue000 Act\ue000 of\ue000 1934,\ue000 as\ue000 amended,\ue000 and\ue000 Section\ue000 27A\ue000 of\ue000 the
Securities\ue000 Act\ue000 of\ue000 1933,\ue000 as\ue000 amended,\ue000 ap\ue000 ply\ue000 to\ue000 forward-looking\ue000 statements\ue000 made\ue000 by\ue000 the\ue000 Registrant.\ue000 The\ue000 reader\ue000 is
cautioned\ue000 that\ue000 no\ue000 statements\ue000 contained\ue000 in\ue000 this\ue000 Form\ue000 8-K\ue000 should\ue000 be\ue000 construed\ue000 as\ue000 a\ue000 guarantee\ue000 or\ue000 assurance\ue000 of\ue000 future
performance\ue000 or\ue000 results.\ue000 These\ue000 forward-looking\ue000 statements\ue000 involve\ue000 risks\ue000 and\ue000 uncertainties,\ue000 including\ue000 those\ue000 identified
within\ue000 this\ue000 Form\ue000 8-K.\ue000 The\ue000 actual\ue000 results\ue000 that\ue000 the\ue000 Registrant\ue000 achieves\ue000 may\ue000 differ\ue000 materially\ue000 from\ue000 any\ue000 forward-looking
statements\ue000 due\ue000 to\ue000 such\ue000 risks\ue000 and\ue000 uncertainties.\ue000 These\ue000 forward-looking\ue000 statements\ue000 are\ue000 based\ue000 on\ue000 current\ue000 expectations,
and\ue000 the\ue000 Registrant\ue000 assumes\ue000 no\ue000 obligation\ue000 to\ue000 update\ue000 this\ue000 information.\ue000 Readers\ue000 are\ue000 urged\ue000 to\ue000 carefully\ue000 review\ue000 and
consider\ue000 the\ue000 various\ue000 disclosures\ue000 made\ue000 by\ue000 the\ue000 Registrant\ue000 in\ue000 this\ue000 Form\ue000 8-K\ue000 and\ue000 in\ue000 the\ue000 Registrant's\ue000 other\ue000 reports\ue000 filed
with\ue000 the\ue000 Securities\ue000 and\ue000 Exchange\ue000 Commission\ue000 that\ue000 attempt\ue000 to\ue000 advise\ue000 interested\ue000 parties\ue000 of\ue000 the\ue000 risks\ue000 and\ue000 factors\ue000 that
may\ue000 affect\ue000 the\ue000 Registrant's\ue000 business.
Note:\ue000 Information\ue000 in\ue000 this\ue000 report\ue000 furnished\ue000 pursuant\ue000 to\ue000 Item\ue000 7\ue000 shall\ue000 not\ue000 be\ue000 deemed\ue000 to\ue000 be\ue000 "filed"\ue000 for\ue000 purposes\ue000 of\ue000 Section
Processed and formatted by SEC Watch - Visit SECWatch.com
Leave a Comment